The FDA report on intraocular lenses.

Australian journal of ophthalmology Pub Date : 1984-02-01
W J Stark, D M Worthen, J T Holladay, P E Bath, M E Jacobs, G C Murray, E T McGhee, M W Talbott, M D Shipp, N E Thomas
{"title":"The FDA report on intraocular lenses.","authors":"W J Stark,&nbsp;D M Worthen,&nbsp;J T Holladay,&nbsp;P E Bath,&nbsp;M E Jacobs,&nbsp;G C Murray,&nbsp;E T McGhee,&nbsp;M W Talbott,&nbsp;M D Shipp,&nbsp;N E Thomas","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Clinical studies of intraocular lenses (IOLs) as investigational devices have been regulated in the United States by the Food and Drug Administration (FDA) since 9 February 1978. As of August 1982, data have been collected on more than one million IOLs implanted. During the last 12 months of the study, 409 000 IOLs were implanted. Visual acuity of 20/40 or better at one year after surgery was present in 85% of over 45 000 cases reviewed. Increasing patient age, surgical problems, postoperative complications, and adverse reactions were factors that reduced the visual acuity. The current trend in the USA is for implantation of posterior chamber and anterior chamber IOLs.</p>","PeriodicalId":78095,"journal":{"name":"Australian journal of ophthalmology","volume":"12 1","pages":"61-9"},"PeriodicalIF":0.0000,"publicationDate":"1984-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian journal of ophthalmology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Clinical studies of intraocular lenses (IOLs) as investigational devices have been regulated in the United States by the Food and Drug Administration (FDA) since 9 February 1978. As of August 1982, data have been collected on more than one million IOLs implanted. During the last 12 months of the study, 409 000 IOLs were implanted. Visual acuity of 20/40 or better at one year after surgery was present in 85% of over 45 000 cases reviewed. Increasing patient age, surgical problems, postoperative complications, and adverse reactions were factors that reduced the visual acuity. The current trend in the USA is for implantation of posterior chamber and anterior chamber IOLs.

FDA关于人工晶状体的报告。
自1978年2月9日以来,美国食品和药物管理局(FDA)对人工晶状体(iol)作为研究设备的临床研究进行了规范。截至1982年8月,已经收集了超过100万例人工晶状体植入的数据。在研究的最后12个月中,共植入了409,000个人工晶状体。术后1年视力达到20/40或更好的病例在45000例中占85%。患者年龄增加、手术问题、术后并发症和不良反应是降低视力的因素。目前在美国的趋势是植入后房型和前房型人工晶状体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信